{"id":"r-ceop90","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Infusion reactions"}]},"_chembl":{"chemblId":"CHEMBL89731","moleculeType":"Small molecule","molecularWeight":"159.14"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This combination regimen uses rituximab, a CD20-targeting monoclonal antibody, to selectively eliminate B cells, combined with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) to provide additional cytotoxic activity. The rituximab component enhances antibody-dependent cellular cytotoxicity and direct apoptosis of CD20-positive cells, while the chemotherapy agents work through multiple mechanisms including DNA alkylation and topoisomerase inhibition.","oneSentence":"R-CEOP90 is a chemotherapy regimen combining rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone, designed to target B-cell malignancies through immunochemotherapy.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:31:02.519Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"B-cell non-Hodgkin lymphoma"},{"name":"Diffuse large B-cell lymphoma (DLBCL)"}]},"trialDetails":[{"nctId":"NCT03213977","phase":"PHASE3","title":"R-DA-EDOCH Versus R-CEOP90, With/Without Upfront Auto-HSCT in Young Patients With High-risk DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fujian Medical University","startDate":"2017-07-10","conditions":"Diffuse Large B-cell Lymphoma","enrollment":475},{"nctId":"NCT01852435","phase":"PHASE3","title":"R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2013-05","conditions":"Diffuse Large B-cell Lymphoma, Follicular Lymphoma Grade 3B","enrollment":648},{"nctId":"NCT03151044","phase":"PHASE3","title":"R±CEOP90 Versus R±CEOP75 in Newly Diagnosed Young Patients With Medium/High-risk DLBCL","status":"UNKNOWN","sponsor":"FENG Ji-feng","startDate":"2016-07","conditions":"Diffuse Large B-cell Lymphoma","enrollment":408}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"R-CEOP90","genericName":"R-CEOP90","companyName":"Fujian Medical University","companyId":"fujian-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"R-CEOP90 is a chemotherapy regimen combining rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone, designed to target B-cell malignancies through immunochemotherapy. Used for B-cell non-Hodgkin lymphoma, Diffuse large B-cell lymphoma (DLBCL).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}